Fig. 2

Tet-29 ameliorates disease by inhibiting CNS infiltration. Female C57BL/6J mice were immunised for EAE and treated daily with 30 mg/kg/day of Tet-29 (n = 24) or the equivalent volume of vehicle (n = 30) by i.p. injection. Healthy mice were treated daily with vehicle. Treatment began on day 5 after EAE induction and animals were sacrificed after 20 days of treatment. Mice were scored daily (a–c). Immune cell populations in the spinal cord (d–g), brain (h–k), and spleen (l–o) were analysed by flow cytometry. Data are pooled from 3 independent experiments and displayed as mean ± SEM, with n = 10 (healthy & vehicle) or 8 (Tet-29) per group. a An interaction between time and treatment group on scores was uncovered with **p < 0.0001 by mixed effects model and *p < 0.05, **p < 0.01, ***p < 0.001 by Sidak’s multiple comparison test. b **p < 0.01 by Student’s unpaired t-test. c ****p < 0.0001 by Mann–Whitney non-parametric test. d–o *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA with Tukey’s multiple comparisons